Chewy Just Popped. Is the Pet Stock a Buy Now?

Chewy guided 2026 revenue to $13.6B–$13.75B (8%–9% growth), topping the Street's ~$13.59B estimate and prompting a double-digit stock move. Q4 revenue rose 8.1% to $3.26B (matched consensus); gross margin expanded 90bps to 29.4% and adjusted EBITDA increased to $162.3M from $124.5M, while adjusted EPS was $0.27 (roughly in line with $0.28 consensus when adjusting for an extra week). Management highlighted expansion of Chewy Vet Care to 18 practices (added 10) and the SmartEquine acquisition, which should contribute roughly $80M of net sales (<1% of revenue), providing new growth levers despite modest overall growth; shares trade at about 21x adjusted earnings.

Analysis

Chewy’s guidance and early CVC traction change the growth vector from pure e-commerce share gains to lifecycle monetization. If CVC scales to a national network (we view 60–100 clinics in 24 months as a realistic mid case given vet hiring constraints), the business can add 200–400 basis points of revenue growth vs a product-only compounding path by increasing high-margin Rx and services spend per active customer and accelerating autoship enrollment among veterinarians’ recurring-purchase cohorts.

Second-order winners include manufacturers of veterinary consumables and pet pharmaceuticals (higher attach rates and recurring fills), regional distribution hubs (more frequent, smaller-order cadence into clinic locations), and diagnostics/telehealth vendors that can be cross-sold into clinic workflows; key losers are low-margin commodity sellers — Amazon retains price pressure on staples but cannot replicate licensed clinic-based services at scale without heavy capex and regulatory friction. SmartEquine represents a structurally higher-ticket, less price-elastic vertical that increases Chewy’s TAM and provides cross-sell scale benefits to diagnostics and pharma suppliers.

Key risks are execution and labor/regulatory supply constraints for rapid clinic rollout, integration risk from M&A (SmartEquine), and margin sensitivity to freight and commodity input shocks. Near-term catalysis (next 3–12 months) will be unit-level economics disclosure for CVC and SmartEquine revenue cadence; longer-term outcomes (12–36 months) hinge on attaining predictable clinic-level LTV uplift and stable gross-margin expansion. Valuation at ~21x EPS already prices modest mid-single-digit organic growth — upside requires measurable service monetization; downside is a 30–40% re-rating if LTV forces fail to materialize or if macro-driven pet spend reverts.

Key Decisions for Investors

• Core position: Buy CHWY (size 1–2% NAV) — 12–24 month horizon. Rationale: capture asymmetric upside if CVC scales to 60–100 clinics and SmartEquine ramps to $150–200M revenue. Risk/reward: target +30–40% upside; plan to cut to flat on failure to demonstrate positive unit economics within 12 months; downside ~-30% if monetization stalls.
• Hedge: Buy 12-month protective puts at ~20–25% OTM sized to 25–50% of the equity notional (cost ~3–6% of the equity exposure). This preserves upside while limiting catastrophic downside from a growth re-rating or a macro pullback within 12 months.
• Options growth lever: Bull call spread on CHWY (12–18 month tenor) sized 20–40% of the core position — buy lower strike / sell 30–40% OTM higher strike to finance premium. Use this to lever the binary outcome of CVC unit economics proving out without overpaying for outright calls.
• Pair trade: Long CHWY / Short WOOF (equal-dollar) — 6–12 month horizon. Rationale: capture execution advantage from Chewy’s digital autoship + clinic funnel vs Petco’s legacy retail footprint. Risk: both suffer in a discretionary-spend downturn; keep a stop-loss at 10% on the pair if correlation breaks down.